News & Insights2021-02-08T17:22:09-05:00

News & Insights

Impact, observations, and insights to advance translational intelligence

Trends & Insights
COVID-19 Data Initiative
Press Releases
Conferences & Events

A Technology-Driven Solution for Optimized Statistical Analysis of Clinical Trial Biomarker Data

Trends & Insights|

May 19, 2021 — Biomarker data generated to support clinical development has multiple roles:

  1. Inclusion in end-of-study regulatory submissions. As such, data must conform to FDA data exchange standards and need SDTM programming for analysis and submission.
  2. Supporting on-study decisions. Data must be stored in an accessible, flexibly structured format to adapt to on-study needs. These diverse needs include data visualization, mock TLFs, materials for investor meetings, posters, and reporting for safety review, data monitoring, and dosing decisions.
  3. Enable deep exploration to generate translational insights. Biomarker data generated during clinical trials presents opportunities for sponsors to further characterize mechanism of action and prioritize additional target pathways for their pipelines.


New Asset for Precision Oncology: Source Biospecimens with Specific Mutations of Interest Using QuartzBio-Supported Repository

Trends & Insights|

May 18, 2021 — Identifying biospecimens with specific genetic alterations can be a significant challenge for research, particularly as teams target variants that occur at extremely low frequencies.

Now, translational researchers have a new resource for exploring the functional impact of genetic alterations. As recently announced, Precision for Medicine’s Biospecimens Solutions group has launched the Precision Oncology Sequencing Initiative (P.O.S.I.), supported by QuartzBio’s industry-leading biomarker data management and computational biology capabilities.


Translational Intelligence: Exploring Immunotherapy Response Signatures with Clinical Trial Genomics Data

Trends & Insights|

May 5, 2021 — As the data generated during a modern clinical trial has dramatically expanded, sponsors must continuously evaluate novel approaches to help bridge the gap between millions of data points and breakthrough scientific insights (a goal we describe as delivering Translational Intelligence). One such example is assessing signatures of “hot” and “cold” tumors.


Career Opportunities at QuartzBio, Part of Precision for Medicine


Join QuartzBio, a fast-paced and rapidly growing team providing tech-enabled solutions to maximize the potential of biomarker data and streamline clinical operations.

We are geneticists, immunologists, statisticians, systems biologists, data scientists, programmers, and software engineers passionate about helping clients pursue biomarker-driven clinical drug development.

Our clients are developing drugs in oncology, immuno-oncology, rare and orphan disease, autoimmune, and many other therapeutic areas.


Webinar On Demand: Exploring IO Signatures in Clinical Trial Genomic Data

Conferences & Events, Trends & Insights|

Watch the webinar on demand:

Title: Translational Intelligence: Exploring IO Signatures in Clinical Trial Genomic Data

Duration: 30 minutes

You will learn how to:

  • Visualize gene alterations and tumor mutational burden (TMB) using heatmaps and tables, with subject and time point granularity. ​
  • Identify genes of interest and candidate signatures using visualization and statistical methods to relate clinical response data and gene expression data to regions of genomic alteration.​
  • Correlate genomic data with known signatures of immuno-oncology (IO) response through integrations with public data, knowledgebases and sponsor data.​
  • Define patient subgroups to generate deeper biological/ mechanistic insights.


Load More Posts